NLRP3 Cancer Research Results

NLRP3, NOD-like receptor pyrin domain-containing protein 3: Click to Expand ⟱
Source:
Type:
NLRP3 (NOD-like receptor pyrin domain-containing protein 3) is a protein that plays a crucial role in the regulation of inflammation and immune responses.
NLRP3 typically has high expression in cancers, with poor prognosis.
For alzheimer's disease:
-NLRP3 is upregulated in Alzheimer's disease (AD)
-NLRP3 is activated in microglia in response to amyloid-β (Aβ) and tau aggregates.
-Promotes tau hyperphosphorylation and spread via inflammation-driven pathways.
Nor, Normal Healthy: Click to Expand ⟱
Normal Healthy
Scientific Papers found: Click to Expand⟱
4434- AgNPs,  SSE,    Sodium Selenite Ameliorates Silver Nanoparticles Induced Vascular Endothelial Cytotoxic Injury by Antioxidative Properties and Suppressing Inflammation Through Activating the Nrf2 Signaling Pathway
- vitro+vivo, Nor, NA
*ROS↓, *Inflam↓, *NLRP3↓, *NF-kB↓, *NRF2↑, *HO-1↑, *toxicity↓,
2661- AL,    Allicin alleviates traumatic brain injury-induced neuroinflammation by enhancing PKC-δ-mediated mitophagy
- in-vivo, Nor, NA
*TNF-α↓, *IL1β↓, *IL6↓, *ROS↓, *NLRP3↓, *TLR4↓, *PKCδ↑, neuroP↑,
6510- BCP,  CBD,    Cannabidiol and Beta-Caryophyllene Combination Attenuates Diabetic Neuropathy by Inhibiting NLRP3 Inflammasome/NFκB through the AMPK/sirT3/Nrf2 Axis
- in-vivo, Nor, NA
*MMP↓, *ROS↑, *BloodF↑, *Pain↓, *antiOx↑, *Inflam↓, *AMPK↑, *SIRT3↑, *NRF2↑, *PINK1↑, *PARK2↑, *LC3B↑, *Beclin-1/ATG6↑, *TFAM↑, *NLRP3↓, *NF-kB↓, *COX2/PTGS2↓, *p62↓, *NP/CIPN↓,
5755- CA,    Caffeic Acid as a Promising Natural Feed Additive: Advancing Sustainable Aquaculture
- Review, Nor, NA
*Imm↑, *Inflam↓, *Bacteria↓, *eff↑, *ROS↓, *MDA↓, *Catalase↑, *GSH↑, *TAC↑, *NF-kB↓, *NLRP3↓, *eff↑, *AST↓, *ALAT↓, *SOD↑, *GSTA1↑,
6011- CGA,    Chlorogenic Acid’s Role in Metabolic Health: Mechanisms and Therapeutic Potential
- Review, Nor, NA
*BioAv↓, *antiOx↑, *Inflam↓, *Bacteria↓, *hepatoP↑, *cardioP↑, *neuroP↑, *ROS↓, *NF-kB↓, *NRF2↑, *Obesity↓, *GutMicro↑, *AntiAg↑, *cardioP↑, *AntiDiabetic↑, *NLRP3↓, *OCLN↓, *VEGF↓, BioAv↝,
3225- EGCG,    Epigallocatechin‐3‐Gallate Ameliorates Diabetic Kidney Disease by Inhibiting the TXNIP/NLRP3/IL‐1β Signaling Pathway
- in-vitro, Nor, NA - in-vivo, Nor, NA
*RenoP↑, *NLRP3↓, *TXNIP↓, *ASC↓, *Casp1↓, *IL1β↓, *ROS↓, *TNF-α↓, *IL6↓, *IL18↓,
3224- EGCG,    Epigallocatechin-3-Gallate Prevents Acute Gout by Suppressing NLRP3 Inflammasome Activation and Mitochondrial DNA Synthesis
- in-vitro, Nor, NA
*Casp1↓, *NLRP3↓, *Inflam↓,
6784- EGCG,    Dietary (−)-Epigallocatechin Gallate (EGCG): State-of-the-Art Advances in Bioactivities, Bioavailability Enhancement Strategies, and Applications in Nutrition and Health
- Review, Nor, NA
*antiOx↑, *Inflam↓, *AntiCan↑, *cardioP↑, *neuroP↑, *GutMicro↑, *AntiBio↑, *ROS↓, *TNF-α↓, *IL6↓, TumCP↓, *LDL↓, *NO↓, *Obesity↓, *p‑tau↓, *Aβ↓, *NRF2↑, *SOD↑, *Catalase↑, *GPx↑, *NLRP3↓, *mTOR↓, TumCCA↑, NRF2↓, Apoptosis↑, SIRT1↓, miR-25-5p↓, PARP↑, Casp3↑, Casp9↑, ER Stress↑, TumAuto↑, EMT↓, TumCI↓, TumCMig↓, TGF-β↓, Smad1↓, STAT3↓, VEGF↓, angioG↓, Imm↑, EGFR↓, *GutMicro↑, *Bacteria↓, *AntiViral↑, *BioAv↓, *BioAv↑, *eff↑, *BioAv↑, eff↑, ChemoSen↑, *toxicity↝,
6825- EMD,    Advances in the pharmacological effects and molecular mechanisms of emodin in the treatment of metabolic diseases
- Review, Nor, NA
*Inflam↓, *AntiTum↑, *Bacteria↓, *Imm↑, *glucose↓, *RenoP↑, *TLR4↓, *MyD88↓, *NLRP3↓, *NF-kB↓, *PI3K↓, *mTOR↓, *GSK‐3β↓, *Hif1a↓, *VEGF↓, *GutMicro↑, *Obesity↓, *AntiDiabetic↑, *AMPK↑, *PPARγ↑, *PPARγ↓, *toxicity↝, *hepatoP↑, *AST↓, *ALAT↓,
7560- HYP,    Hyperoside: A Review of Its Structure, Synthesis, Pharmacology, Pharmacokinetics and Toxicity
- Review, Nor, NA - Review, AD, NA
*RenoP↓, Casp3↑, Casp8↑, MDA↑, GSH↓, SOD↓, Catalase↓, VEGF↓, Bcl-2↓, TumCG↓, p‑Akt↓, PI3K↓, TumCCA↑, TumCP↓, BMP7/OP1↓, *ZO-1↑, *BBB↝, *p‑Akt↑, *GSK‐3β↑, *SOD↑, *Catalase↑, *GSH↑, *SIRT1↑, *NF-kB↓, *IL1β↓, *IL6↓, *IL8↓, *TNF-α↓, *ROS↓, *MDA↓, *BAX↓, *Casp3↓, *Bcl-2↑, *BDNF↑, *TrkB↑, *NGF↑, *Apoptosis↓, *cardioP↑, *AST↓, *hepatoP↑, *AST↓, *ALAT↓, *MDA↓, *BACH1↓, *neuroP↑, *Stroke↓, *ICAM-1↓, *VCAM-1↓, *TLR4↓, *COX2/PTGS2↓, *RenoP↑, *NLRP3↓, *Casp1↓, *ASC↓, *BioAv↓, *BioAv↑, *toxicity↓,
7760- ISL,    Pharmacological Potentials and Delivery Strategies of Isoliquiritigenin: Challenges and Advances in Enhancing Bioavailability
- Review, Nor, NA
*BioAv↓, GlucoseCon↓, LDH↓, PDK1 / PDPK1↓, Glycolysis↓, mt-OXPHOS↓, Bax:Bcl2↓, cl‑Casp3↑, cl‑Casp9↑, Apoptosis↑, Hif1a↓, ROS↑, *AntiDiabetic↑, *cardioP↑, *RenoP↑, *ROS↓, *NF-kB↓, *NLRP3↓, *Pyro↓, *antiPs↑, *IL6↓, *IL8↓, BioAv↑, BioAv↑, BioAv↑,
7780- ISL,    Isoliquiritigenin alleviates LPS/ D-GalN-induced acute liver failure by activating the PGC-1α/ Nrf2 pathway to reduce oxidative stress and inflammatory response
- in-vivo, Nor, NA
*hepatoP↑, *ROS↓, *PGC-1α↝, *NRF2↑, *HO-1↑, *NQO1↝, *Keap1↝, *GCLC↝, *GCLM↝, *NLRP3↓, *IL1β↓, *IL6↓, *TNF-α↓, *MIP2↓, *Bax:Bcl2↓, *cl‑Casp3↓, *Inflam↓, *Apoptosis↓,
7884- isoO,    Orientin Ameliorates LPS-Induced Inflammatory Responses through the Inhibitory of the NF-κB Pathway and NLRP3 Inflammasome
- in-vitro, Nor, RAW264.7
*TNF-α↓, *IL6↓, *IL1β↓, *IL18↓, *PGE2↓, *NO↓, *COX2/PTGS2↓, *iNOS↓, *NF-kB↓, *NLRP3↓,
7874- isoO,    Isoorientin protects lipopolysaccharide-induced acute lung injury in mice via modulating Keap1/Nrf2-HO-1 and NLRP3 inflammasome pathways
- in-vivo, Nor, NA
*ROS↓, *IL6↓, *NRF2↑, *HO-1↑, *Keap1↓, *NOD1↓, *NLRP3↓, *Casp1↓, *ASC↓, *IL1β↓, *Apoptosis↓,
7814- ISQ,    Isoquercitrin Attenuates Steatohepatitis by Inhibition of the Activated NLRP3 Inflammasome through HSP90
- in-vivo, Nor, NA
*ROS↓, *AntiCan↑, *cardioP↑, *AntiDiabetic↑, *NLRP3↓, *HSP90↓, *AST↓, *ALAT↓,
8230- LCA,    The Ameliorative Role of Lico A on Aflatoxin B1-Triggered Hepatotoxicity Partially by Activating Nrf2 Signal Pathway
- vitro+vivo, Nor, NA
*hepatoP↑, *ROS↓, *TLR4↓, *NF-kB↓, *MAPK↓, *NLRP3↓, *NRF2↑, *Inflam↓, *Pyro↓,
2921- LT,    Luteolin as a potential hepatoprotective drug: Molecular mechanisms and treatment strategies
- Review, Nor, NA
*hepatoP↑, *AMPK↑, *SIRT1↑, *ROS↓, STAT3↓, TNF-α↓, NF-kB↓, *IL2↓, *IFN-γ↓, *GSH↑, *SREBP1/SREBF1↓, *ZO-1↑, *TLR4↓, BAX↑, Bcl-2↓, XIAP↓, Fas↑, Casp8↑, Beclin-1/ATG6↑, *TXNIP↓, *Casp1↓, *IL1β↓, *IL18↓, *NLRP3↓, *MDA↓, *SOD↑, *NRF2↑, *ER Stress↓, *ALAT↓, *AST↓, *iNOS↓, *IL6↓, *HO-1↑, *NQO1↑, *PPARα↑, *ATF4↓, *CHOP/DDIT3↓, *Inflam↓, *antiOx↑, *GutMicro↑,
3265- Lyco,    Lycopene inhibits pyroptosis of endothelial progenitor cells induced by ox-LDL through the AMPK/mTOR/NLRP3 pathway
- in-vitro, Nor, NA
*AMPK↑, *mTOR↓, *NLRP3↓, *Pyro↓,
3471- MF,    The prevention effect of pulsed electromagnetic fields treatment on senile osteoporosis in vivo via improving the inflammatory bone microenvironment
- in-vivo, Nor, NA
*BMD↑, *NLRP3↓, *proCasp1↓, *cl‑Casp1↓, *IL1β↓, *GSDMD↓,
2056- PB,    Endoplasmic Reticulum Stress Induces ROS Production and Activates NLRP3 Inflammasome Via the PERK-CHOP Signaling Pathway in Dry Eye Disease
- in-vitro, Nor, HCE-2
*ROS↓, *NLRP3↓, *IL1β↓, *TXNIP↑, *ER Stress↓,
2338- QC,    Quercetin: A Flavonoid with Potential for Treating Acute Lung Injury
- Review, Nor, NA
*SIRT1↑, *NLRP3↓, *Inflam↓, *TNF-α↓, *IL1β↓, *IL6↓, *PKM2↓, *HO-1↑, *ROS↓, *NO↓, *MDA↓, *antiOx↑, *COX2/PTGS2↓, *HMGB1↓, *iNOS↓, *NF-kB↓,
2339- QC,    Quercetin protects against LPS-induced lung injury in mice via SIRT1-mediated suppression of PKM2 nuclear accumulation
- in-vivo, Nor, NA
*Inflam↓, *antiOx↑, *NLRP3↓, *Sepsis↓, *PKM2↓, *SIRT1↓,
3075- RES,  Rad,    The Protection Effect of Resveratrol Against Radiation-Induced Inflammatory Bowel Disease via NLRP-3 Inflammasome Repression in Mice
- in-vivo, Nor, NA
*SIRT1↑, *radioP↑, *NLRP3↓, *Weight↑, *IL1β↓,
3073- RES,    Resveratrol inhibits NLRP3 inflammasome activation by preserving mitochondrial integrity and augmenting autophagy
- in-vitro, Nor, NA
*NLRP3↓, *mtDam↓, *p38↑,
3069- RES,    Resveratrol Inhibits NLRP3 Inflammasome-Induced Pyroptosis and miR-155 Expression in Microglia Through Sirt1/AMPK Pathway
- in-vitro, Nor, N9
*antiOx↑, *Inflam↓, *ROS↓, *NF-kB↓, *AMPK↑, *SIRT1↑, *miR-155↓, *NLRP3↓,
4738- Se,  doxoR,    Selenium Attenuates Doxorubicin-Induced Cardiotoxicity Through Nrf2-NLRP3 Pathway
- NA, Nor, NA
*NRF2↑, *NLRP3↓, *cardioP↑,
3186- SFN,    A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet
- in-vivo, Nor, NA
*NLRP3↓, *ASC↓, *Casp1↓, *IL1β↓, *ALAT↓, *AST↓, *AMPK↑, *mTOR↓, *P70S6K↓,
3185- SFN,    Sulforaphane decreases oxidative stress and inhibits NLRP3 inflammasome activation in a mouse model of ulcerative colitis
- in-vivo, Nor, RAW264.7
*IL18↓, *IL1β↓, *NLRP3↓, *Inflam↓,
3420- TQ,    Thymoquinone alleviates the accumulation of ROS and pyroptosis and promotes perforator skin flap survival through SIRT1/NF-κB pathway
- in-vitro, Nor, HUVECs - in-vitro, NA, NA
*NF-kB↓, *NLRP3↓, *angioG↑, *MMP9↑, *VEGF↑, *OS↑, *Pyro?, *ROS↓, *Apoptosis↓, *SIRT1↑, *SOD1↑, *HO-1↑, *eNOS↑, *ASC?, *Casp1↓, *IL1β↓, *IL18↓,
3125- VitC,    Vitamin C inhibits NLRP3 inflammasome activation and delays the development of age-related hearing loss in male C57BL/6 mice
- in-vivo, Nor, NA
*Hear↑, *Inflam↓, *NLRP3↓,
3127- VitC,    NLRP3_inflammasome_by_scavenging_mitochondrial_ROS">Vitamin C inhibits the activation of the NLRP3 inflammasome by scavenging mitochondrial ROS
- in-vitro, Nor, NA - in-vivo, Nor, NA
*NLRP3↓, *AIM2↓, *mt-ROS↓, *IL1β↓,

Showing Research Papers: 1 to 31 of 31

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 31

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

BMP7/OP1↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

Catalase↓, 1,   GSH↓, 1,   MDA↑, 1,   NRF2↓, 1,   mt-OXPHOS↓, 1,   ROS↑, 1,   SOD↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

GlucoseCon↓, 1,   Glycolysis↓, 1,   LDH↓, 1,   PDK1 / PDPK1↓, 1,   SIRT1↓, 1,  

Cell Death(tgid=5) ⓘ

p‑Akt↓, 1,   Apoptosis↑, 2,   BAX↑, 1,   Bax:Bcl2↓, 1,   Bcl-2↓, 2,   Casp3↑, 2,   cl‑Casp3↑, 1,   Casp8↑, 2,   Casp9↑, 1,   cl‑Casp9↑, 1,   Fas↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

miR-25-5p↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

ER Stress↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EMT↓, 1,   PI3K↓, 1,   STAT3↓, 2,   TumCG↓, 1,  

Migration(tgid=13) ⓘ

Smad1↓, 1,   TGF-β↓, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   EGFR↓, 1,   Hif1a↓, 1,   VEGF↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Imm↑, 1,   NF-kB↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 3,   BioAv↝, 1,   ChemoSen↑, 1,   eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 1,   LDH↓, 1,  

Functional Outcomes(tgid=23) ⓘ

neuroP↑, 1,  
Total Targets: 54

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiBio↑, 1,   NOD1↓, 1,   Stroke↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 7,   Catalase↑, 3,   GCLC↝, 1,   GCLM↝, 1,   GPx↑, 1,   GSH↑, 3,   GSTA1↑, 1,   HO-1↑, 6,   Keap1↓, 1,   Keap1↝, 1,   MDA↓, 5,   NQO1↑, 1,   NQO1↝, 1,   NRF2↑, 9,   PARK2↑, 1,   ROS↓, 17,   ROS↑, 1,   mt-ROS↓, 1,   SIRT3↑, 1,   SOD↑, 4,   SOD1↑, 1,   TAC↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↓, 1,   mtDam↓, 1,   PGC-1α↝, 1,   PINK1↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 6,   AMPK↑, 6,   glucose↓, 1,   LDL↓, 1,   PKM2↓, 2,   PPARα↑, 1,   PPARγ↓, 1,   PPARγ↑, 1,   SIRT1↓, 1,   SIRT1↑, 6,   SREBP1/SREBF1↓, 1,  

Cell Death(tgid=5) ⓘ

p‑Akt↑, 1,   Apoptosis↓, 4,   BAX↓, 1,   Bax:Bcl2↓, 1,   Bcl-2↑, 1,   Casp1↓, 7,   cl‑Casp1↓, 1,   proCasp1↓, 1,   Casp3↓, 1,   cl‑Casp3↓, 1,   GSDMD↓, 1,   iNOS↓, 3,   MAPK↓, 1,   p38↑, 1,   Pyro?, 1,   Pyro↓, 3,  

Transcription & Epigenetics(tgid=7) ⓘ

TFAM↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↓, 1,   ER Stress↓, 2,   HSP90↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↑, 1,   LC3B↑, 1,   p62↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

GSK‐3β↓, 1,   GSK‐3β↑, 1,   mTOR↓, 4,   P70S6K↓, 1,   PI3K↓, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,   BACH1↓, 1,   miR-155↓, 1,   MMP9↑, 1,   PKCδ↑, 1,   TXNIP↓, 2,   TXNIP↑, 1,   VCAM-1↓, 1,   ZO-1↑, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↑, 1,   ATF4↓, 1,   eNOS↑, 1,   Hif1a↓, 1,   NO↓, 3,   VEGF↓, 2,   VEGF↑, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↝, 1,   OCLN↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

AIM2↓, 1,   ASC?, 1,   ASC↓, 4,   COX2/PTGS2↓, 4,   HMGB1↓, 1,   ICAM-1↓, 1,   IFN-γ↓, 1,   IL18↓, 5,   IL1β↓, 15,   IL2↓, 1,   IL6↓, 10,   IL8↓, 2,   Imm↑, 2,   Inflam↓, 15,   MIP2↓, 1,   MyD88↓, 1,   NF-kB↓, 12,   PGE2↓, 1,   TLR4↓, 5,   TNF-α↓, 7,  

Synaptic & Neurotransmission(tgid=18) ⓘ

BDNF↑, 1,   NGF↑, 1,   p‑tau↓, 1,   TrkB↑, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,   NLRP3↓, 31,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 4,   BioAv↑, 3,   eff↑, 3,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 6,   AST↓, 7,   BloodF↑, 1,   BMD↑, 1,   GutMicro↑, 5,   IL6↓, 10,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 2,   AntiDiabetic↑, 4,   antiPs↑, 1,   AntiTum↑, 1,   cardioP↑, 7,   Hear↑, 1,   hepatoP↑, 6,   neuroP↑, 3,   NP/CIPN↓, 1,   Obesity↓, 3,   OS↑, 1,   Pain↓, 1,   radioP↑, 1,   RenoP↓, 1,   RenoP↑, 4,   toxicity↓, 2,   toxicity↝, 2,   Weight↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiViral↑, 1,   Bacteria↓, 4,   Sepsis↓, 1,  
Total Targets: 142

Scientific Paper Hit Count for: NLRP3, NOD-like receptor pyrin domain-containing protein 3
3 EGCG (Epigallocatechin Gallate)
3 Resveratrol
2 Isoliquiritigenin
2 isoorientin
2 Quercetin
2 Sulforaphane (mainly Broccoli)
2 Vitamin C (Ascorbic Acid)
1 Silver-NanoParticles
1 Selenite (Sodium)
1 Allicin (mainly Garlic)
1 Beta-Caryophyllene
1 Cannabidiol
1 Caffeic acid
1 Chlorogenic acid
1 Emodin
1 Hyperoside
1 isoquercitrin
1 Licochalcone A
1 Luteolin
1 Lycopene
1 Magnetic Fields
1 Phenylbutyrate
1 Radiotherapy/Radiation
1 Selenium
1 doxorubicin
1 Thymoquinone
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:49  Cells:%  prod#:%  Target#:908  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page